J&J's Topamax helps alcoholics quit

What do you call a migraine drug that could help alcoholics quit drinking? A big-time marketing opportunity--if it weren't going off patent next year.

A new study shows that the Johnson & Johnson remedy Topamax, used in epilepsy and migraine, can help alcoholics stop craving liquor. The study was funded in part by the company, but it says it doesn't plan to seek FDA approval for its use against alcoholism. Doctors could prescribe it off-label, however.

J&J didn't put out a press release touting the research, perhaps because that could be construed as promoting the drug for an off-label use. The study, published in the Journal of the American Medical Association, will take care of that--with the help of all the attendant media attention. Including ours.

- check out the article from the Washington Post

Read more on: Johnson & Johnson

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.